

Authors:

Tai Hwan Park (Seoul Medical Center)
Keun-Sik Hong (Ilsan Paik Hospital, Inje University)
Yong-Jin Cho (Ilsan Paik Hospital, Inje University)
Wi-Sun Ryu (JLK Inc.)
Dong-Eog Kim (Dongguk University Ilsan Hospital)
Man-Seok Park (Chonnam National University Hospital)
Kang-Ho Choi (Chonnam National University Hospital)
Joon-Tae Kim (Chonnam National University Hospital)
Jihoon Kang (Seoul National University Bundang Hospital)
Beom Joon Kim (Seoul National University Bundang Hospital)
Moon-Ku Han (Seoul National University College of Medicine, Seoul National University Bundang Hospital)
Jun Lee (Yeungnam University Hospital)
Jae-Kwan Cha (Dong-A University Hospital)
Dae-Hyun Kim (Dong-A University Hospital)
Jae Guk Kim (Eulji University Hospital, Eulji University College of Medicine)
Soo Joo Lee (Eulji University Hospital)
Jee-Hyun Kwon (Ulsan university college of medicine)
Wook-Joo Kim (Ulsan University Hospital, Ulsan University College of Medicine)
Dong-Ick Shin (Chungbuk National University Hospital)
Kyu Sun Yum (Chungbuk National University)
Sung-Il Sohn (Dongsan Hospital, Keimyung University School of Medicine)
Jeong-Ho Hong (Keimyung University Dongsan Hospital)
Jay Chol Choi (Jeju National University)
Byung-Chul Lee (Hallym University Sacred Heart Hospital, Hallym University College of Medicine)
Kyung-Ho Yu (Hallym University)
Mi Sun Oh (Hallym University Sacred Heart Hospital, University College of Medicine)
Jong-Moo Park (Uijeongbu Eulji Medical Center, Eulji University)
Kyunik Kang (Nowon Eulji Medical Center, Eulji University)
Kyungbok Lee (Soonchunhyang University College of Medicine)
Sang-Hwa Lee (Chuncheon Sacred Heart Hospital, Hallym University College of Medicine)
Hae-Bong Jeong (Chung-Ang University Hospital)
Kwang-Yeol Park (Chung-Ang University College of Medicine, Chung-Ang University Hospital)
Ji Sung Lee (Asan Medical Center)
Juneyoung Lee (Korea University College of Medicine)
Philip Gorelick (Northwestern University)
Hee-Joon Bae (Seoul National University Bundang Hospital)

Temporal Trends in Stroke Management and Outcomes between 2011 and 2020: Results from a Nationwide Multicenter Registry

Authors: Tai Hwan Park, MD, PhD; Keun-Sik Hong, MD, PhD; Yong-Jin Cho, MD, PhD; Wi-Sun Ryu, MD, PhD; Dong-Eog Kim, MD, PhD; Man-Seok Park, MD, PhD; Kang-Ho Choi, MD, PhD; Joon-Tae Kim, MD, PhD; Jihoon Kang, MD, PhD; Beom-Joon Kim, MD, PhD; Moon-Ku Han, MD, PhD; Jun Lee, MD, PhD; Jae-Kwan Cha, MD, PhD; Dae-Hyun Kim, MD, PhD; Jae Guk Kim, MD, PhD; Soo Joo Lee, MD, PhD; Jee-Hyun Kwon, MD, PhD; Wook-Joo Kim, MD, PhD; Dong-Ick Shin, MD, PhD; Kyu Sun Yum, MD, PhD; Sung Il Sohn, MD, PhD; Jeong-Ho Hong, MD, PhD; Jay Chol Choi, MD, PhD; Byung-Chul Lee, MD, PhD; Kyung-Ho Yu, MD, PhD; Mi-Sun Oh, MD, PhD; Jong-Moo Park, MD, PhD; Kyusik Kang, MD, PhD; Kyungbok Lee, MD, PhD; Sang-Hwa Lee, MD, PhD; Hae-Bong Jeong, MD; Kwang-Yeol Park, MD, PhD; Ji Sung Lee, PhD; Juneyoung Lee, PhD; Philip B. Gorelick, MD, MPH; Hee-Joon Bae, MD, PhD

Tai Hwan Park, Seoul Medical Center, Department of Neurology, Seoul, Korea

Keun-Sik Hong, Yong-Jin Cho, Ilsan Paik Hospital, Inje University, Department of Neurology, Goyang, Korea

Wi-Sun Ryu, Dong-Eog Kim, Dongguk University Ilsan Hospital, Department of Neurology, Goyang, Korea

Man-Seok Park, Kang-Ho Choi, Joon-Tae Kim, Chonnam National University Hospital, Department of Neurology, Gwangju, Korea

Jihoon Kang, Beom-Joon Kim, Moon-Ku Han, Seoul National University Bundang Hospital,
Department of Neurology, Cerebrovascular Center, Seongnam, Korea

Jun Lee, Yeungnam University Hospital, Department of Neurology, Daegu, Korea

Jae-Kwan Cha, Dae-Hyun Kim, Dong-A University Hospital, Department of Neurology,
Busan, Korea

Jae Guk Kim, Soo Joo Lee, Eulji University Hospital, Eulji University, Department of
Neurology, Daejeon, Korea

Jee-Hyun Kwon, Wook-Joo Kim, Ulsan University College of Medicine, Department of
Neurology, Ulsan, Korea

Dong-Ick Shin, Kyu Sun Yum, Chungbuk National University Hospital, Department of
Neurology, Cheongju, Korea

Sung Il Sohn, Jeong-Ho Hong, Keimyung University Dongsan Medical Center, Department
of Neurology, Daegu, Korea

Jay Chol Choi, Jeju National University Hospital, Jeju National University School of
Medicine, Department of Neurology, Jeju, Korea

Byung-Chul Lee, Kyung-Ho Yu, Mi-Sun Oh, Hallym University Sacred Heart Hospital,
Department of Neurology, Anyang, Korea

Jong-Moo Park, Uijeongbu Eulji Medical center, Eulji University, Department of Neurology,
Uijeongbu, Korea

Kyusik Kang, Nowon Eulji Medical Center, Eulji University School of Medicine,
Department of Neurology, Seoul, Korea

Kyungbok Lee, Soonchunhyang University Hospital, Department of Neurology, Seoul, Korea

Sang-Hwa Lee, Hallym University Chuncheon Sacred Heart Hospital, Department of Neurology, Gangwon-do, Korea

Hae-Bong Jeong, Kwang-Yeol Park, Chung-Ang University Hospital, Department of Neurology, Seoul, Korea

Ji Sung Lee, Asan Medical Center, Clinical Research Center, Seoul, Korea

Juneyoung Lee, Korea University College of Medicine, Department of Biostatistics, Seoul, Korea

Philip B. Gorelick, Northwestern University Feinberg School of Medicine, Davee Department of Neurology, Chicago, IL, USA

Hee-Joon Bae; Seoul National University Bundang Hospital, Department of Neurology, Cerebrovascular Center, Seongnam, Korea

Short title: **Temporal Trends in Stroke Management and Outcome**

Search Terms: **Temporal trends, Stroke, Management, Outcome**

Submission Type: **Research Article**

Title Character count: **125**

Number of References: **38**

Number of Tables: **3**

Number of Figures: **1**

Word count of Abstract: **304**

Word count of Paper: **5,977**

***Corresponding author:** Hee-Joon Bae, MD, PhD, FAHA

Department of Neurology, Seoul National University College of Medicine, Seoul National

University Bundang Hospital, 82 Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si,

Gyeonggi-do 13620, Republic of Korea

E-mail: braindoc@snu.ac.kr

Fax: +82-31-787-45

Abstract

Background: There have been significant advancements in the treatment of ischemic stroke including stent retrievers for endovascular thrombectomy, new oral anticoagulants for atrial fibrillation, dual antiplatelet therapy for stroke prevention, and statins for atherosclerotic stroke. This study aims to evaluate temporal trends of these treatments and related clinical outcomes through a decade-long trend analysis, utilizing data from a comprehensive, national, multicenter stroke registry. We also seek to identify areas in need of improvement.

Methods: This analysis involved patients with ischemic stroke or transient ischemic attack registered prospectively in the Clinical Research Center for Stroke-Korea-National Institute of Health (CRCS-K-NIH) registry between 2011 and 2020. We examined temporal trends in risk factors, etiologic subtypes, acute management strategies, and outcomes for up to one year post-stroke. Generalized linear mixed models were employed to account for center clustering.

Results: Among 77,662 patients over 10 years, the average age increased by 2.2 years in men and 2.4 years in women. Notably, in-hospital neurological deterioration, 3-month and 1-year mortality, and cumulative incidence of recurrent stroke within one year showed significant decreases over time after adjustments for age, sex, and initial stroke severity ($P_{trend}'s < 0.01$). However, functional outcomes at 3 months and 1 year remained unchanged. The use of endovascular thrombectomy increased from 5.4% in 2011 to 10.6% in 2020. There was also an increase in the prescription of anticoagulants for atrial fibrillation, dual antiplatelet therapy, statins, and stroke unit care. Contrarily, the rate of intravenous thrombolysis showed a slight decline.

Conclusions: This study points to a reduction in mortality and risk of recurrent stroke over the past decade, paralleling enhancement in acute and preventive stroke management. Nevertheless, the decline in use of intravenous thrombolysis and the stagnation of functional

outcomes may signal the need for further investigation to identify underlying causes of these trends and counterstrategies to mitigate risks.

Introduction

Over the last decade, ischemic stroke treatment has seen significant advancements with the introduction of stent retrievers for endovascular thrombectomy (EVT),¹ novel oral anticoagulants (NOACs) for atrial fibrillation,²⁻⁴ dual antiplatelet therapy (DAPT) for minor strokes or high-risk transient ischemic attacks (TIAs),^{5,6} and high-dose statins for atherosclerotic stroke prevention.^{7,8} While these treatments have been successfully integrated into clinical practice, their comprehensive impact on clinical outcomes warrants further investigation.

Evaluating these treatments' effectiveness requires examining both of stroke recurrence and functional outcomes, as their impacts may vary based on the outcome measured. For example, appropriate antithrombotic selection can reduce stroke recurrence,¹¹ and wider use of recanalization therapies and strategies preventing neurological deterioration during hospitalization may enhance functional outcomes.^{1,12}

Despite a reported decline in stroke mortality and case fatality rates,¹³⁻¹⁶ insights into non-mortality stroke outcomes remain limited. Previous studies, like a German population-based study¹⁷ on recurrent stroke risk over 20 years and a comprehensive Japanese study of ischemic stroke cases¹⁸ reporting improving functional outcomes at discharge between 2000 and 2019, have not fully addressed long-term outcomes or the nuances of early treatment and stroke characteristics.

The Clinical Research Collaboration for Stroke in Korea-National Institute of Health (CRCS-K-NIH) registry, initiated in 2008, offers a rich dataset on stroke characteristics, treatments, and outcomes.¹⁹ Utilizing this registry database, we aim to outline trends in stroke outcomes, including functional outcomes at 3 months and 1 year, major vascular events, and mortality within the first year. It also seeks to assess trends in acute stroke treatments from 2011 to 2020, aiming to pinpoint areas for quality enhancement.

Methods

Study Design and Participants

This trend analysis focused on acute ischemic stroke (AIS) or TIA patients admitted from January 1, 2011, to December 31, 2020, identified within the CRCS-K-NIH registry.^{19,20} The registry includes demographics, clinical presentation, risk factors, treatments, and quality indicators, collected via a web-based system following predefined protocols.

Outcome Measures

We analyzed in-hospital neurological deterioration (ND), 3-month and 1-year functional outcomes, and major vascular events and mortality within the first year, assessed through structured interviews by trained nurse coordinators or physicians during follow-up.

Data Quality and Fidelity

Data integrity was maintained via monthly downloads, verification, steering committee reviews, and audits. Further details on quality and fidelity of data are available on the CRCS-K website (<http://crcs-k.strokedb.or.kr/eng/>).^{19,20}

Study variables

Evaluated variables included traditional stroke risk factors, pre-stroke medications, stroke severity (NIH Stroke Scale [NIHSS]), stroke onset, onset-to-arrival (OTA) time, and stroke etiological subtypes. Diagnostic assessments covered diffusion-weighted imaging (DWI), perfusion-weighted imaging (PWI), CT/MR angiography, echocardiography, and 24-hour Holter monitoring. Treatment variables encompassed intravenous thrombolysis (IVT) and EVT use, door-to-needle (DTN) and door-to-puncture (DTP) times, and discharge

medications. Outcomes measured included ND, symptomatic hemorrhagic transformation, hospital stay length, recurrent stroke, modified Rankin Scale (mRS) scores, and mortality. Detailed descriptions of the registry's design and data collection are documented in prior publications.^{19,20}

Ethics statement

Institutional review boards (IRBs) at all involved centers approved the collection of clinical information in the CRCS-K-NIH registry to monitor and improve the quality and outcomes of stroke care, granting a waiver of informed consent due to data anonymization and minimal participant risk. The IRBs also approved this research's specific use of the registry database.

Statistical analysis

Baseline characteristics, acute treatments, and outcomes were analyzed by calendar year, focusing on the proportions of participants with mild (NIHSS scores <4) and severe strokes (NIHSS scores ≥ 15), OTA time, and the promptness of IVT and EVT administration. We standardized the treatment of missing values and outliers, especially for DTN and DTP times, and length of hospital stay. The details are presented in supplemental material.

Linear regression was applied to continuous variables, and the Cochran–Armitage test to binary variables, to identify temporal trends. We utilized generalized linear mixed models with a random center effect to control for variations in age, sex, and center in examining baseline characteristics, diagnostic evaluations, and discharge medications. The initial NIHSS score was also adjusted in analyses related to acute treatment and outcomes. The usage rate of DAPT at discharge was specifically calculated for patients with non-cardioembolic minor stroke or high-risk TIA.

Visual representations of recanalization therapy trends were depicted in bar graphs for three epochs: 2011–2014, 2015–2017, and 2018–2020, to underscore shifts, particularly post-mid-2010s. Statistical significance was set at a 5% level, with all P values being two-sided. SAS version 9.4 (SAS Institute, Inc., Cary, NC) was employed for statistical analysis.

Data availability

The data analyzed in this study are available from the corresponding author upon reasonable request.

Results

From 2011 to 2020, 77,662 AIS or TIA patients were enrolled in the CRCS-K-NIH registry, with TIA cases constituting 9.3% (n=7,212).

Baseline characteristics

The decade saw an increase in the average age of patients (2.2 years for men, 2.4 years for women) and a 1.8% rise in male patient proportion (Table 1). Despite an older stroke demographic, major modifiable risk factors remained stable. Current smoking decreased by 2.6%, and new dyslipidemia diagnoses fell by 28.8%. Oral anticoagulant and statin use before stroke consistently rose by 27.7% and 10.1%, respectively. Stroke severity at presentation decreased, with the mean initial NIHSS score dropping from 6.0 to 5.4. Mild stroke (NIHSS <4) instances rose, whereas severe strokes (NIHSS ≥15) declined. Emergency room admissions increased by 2.9%, with no significant change in OTA times. Large artery atherosclerosis (LAA) was the leading ischemic stroke subtype, with slight shifts in subtype proportions over time.

Stroke management

Among 70,450 AIS patients, EVT usage increased by 5.2%, while IVT saw a 2% decline (Table 2). These trends were consistent across different patient groups and time frames, notably among older patients and those with cardioembolic (CE) subtype or pre-stroke oral anticoagulant (OAC) use (Figure). DTN times for IVT remained stable, but DTP times for EVT improved significantly, with a 6.1% increase in cases meeting the ≤ 60 min target. Increased utilization of stroke unit care, non-invasive cardiac evaluations, and prescriptions for DAPT, NOACs, and statins at discharge was observed. DAPT use notably doubled in patients with non-CE minor stroke or high-risk TIA, and statin in LAA and OAC use in atrial fibrillation increased, with NOACs surpassing warfarin since 2015.

Outcomes

ND during hospitalization occurred in average 10.4% of patients with AIS or TIA, showing a significant ten-year decline (crude and adjusted P_{trend} 's < 0.01 ; Table 3). Conversely, symptomatic hemorrhagic transformation rates post-recanalization therapy remained stable at 3.0%. Length of hospital stay has decreased significantly.

Follow-up data revealed that 3-month outcomes were documented for 96.2% of participants, and one-year outcomes for 92.1%. There was a marked reduction in mortality rates at both 3 and 12 months (Table 3), peaking in 2014 (8.2% at 3 months and 12.4% at 9 months) before showing a downward trend. Additionally, we observed a significant decrease in the cumulative incidence of recurrent stroke up to one year (crude and adjusted P_{trend} 's < 0.05). This decline in stroke recurrence varied across etiologic subtypes, with LAA and CE subtypes experiencing notable reductions, whereas the small vessel occlusion subtype did not (eTable 1).

An initial analysis indicated an increase in the proportion of patients achieving a mRS score of 0–1 at 3 and 12 months. However, this trend did not persist after adjusting for initial stroke severity (Table 3 and eTable 2). No significant improvement was observed in the proportion of patients with an mRS of 0–2 over the decade.

Discussion

In our analysis of 77,662 patients with AIS or TIA from the 2011-2020 time period in a nationwide multicenter stroke registry, we observed improvement in most stroke outcomes across an aging demographic. This period was characterized by the wide adoption of advanced treatments like EVT, NOAC, DAPT, statin, and stroke unit care. Despite these advancements, we observed a stagnation in functional outcomes, and a decline in the utilization of IVT over the years.

Our study might be the first one to document changes in the occurrence of ND during hospitalization, a condition often linked to stroke progression or recurrence and associated with poorer outcomes.¹² Additionally, the observed decline in stroke recurrence, especially in the LAA and CE subtypes, is also a notable finding. The reductions in ND and stroke recurrence could be explained at least in part by increased use of stroke unit care,²¹ DAPT,^{5,6} NOAC,^{2-4,22} and statin.^{7,8} However, direct evidence of these treatments preventing ND is yet to be established. Enhanced diagnostic approaches, including more frequent use of DWI, angiographic, and cardiac evaluations, also may have contributed to these improvements through better identification and leading to treatment of specific underlying causes of stroke.

The observed decline in ischemic stroke mortality in recent decades¹³⁻¹⁵ can be attributed to better control of vascular risk factors²³ and advancements in in-hospital management.²⁴ Interestingly, this decline became more pronounced following 2015, aligning with the seminal EVT trials,²⁵⁻²⁷ with our data indicating a peak in mortality in 2014 followed

by a notable decrease from 2015 onwards (Table 3). Additionally, the observed reduction in stroke severity may have contributed to improved outcomes. However, our analysis, adjusted for stroke severity, indicates that outcomes have improved independently of stroke severity, suggesting other contributing factors to these positive trends.

Contrary to other studies indicating a rise in major vascular risk factors,^{14,16,28} our study found an unexpected decrease in the prevalence of hypertension and atrial fibrillation, despite an older population (Table 1). In Korea, hypertension management has improved considerably, leading to a reduced prevalence of hypertension in the general population from 1998 to 2018.²⁹ Additionally, the increased use of oral anticoagulants for atrial fibrillation, particularly since the introduction of NOAC reimbursement in South Korea for high-risk patients in 2015, may explain the declining prevalence in AIS patients.⁹ The rise in newly diagnosed atrial fibrillation cases could be attributed to enhanced primary prevention and increased cardiac evaluation. However, the stable proportion of most newly diagnosed risk factors during hospitalization over the decade suggests that primary prevention efforts still leave room for improvement.

The observed reductions in LAA and CE subtypes may also be linked to improved preventive strategies. The decline in LAA, mirroring trends seen in Western countries,³⁰ could be attributed to increased statin use. Similarly, the reduction in CE might be due to the expanded use of NOACs in patients with atrial fibrillation. The decrease in initial stroke severity observed in our study may also result from prestroke statin³¹ or NOAC administration.³² The increase in strokes of unknown etiology highlights the potential need for broader application of advanced diagnostic tools, such as implantable loop recorders, to enhance identification of stroke etiology.

Surprisingly, we observed no improvement in functional outcomes during our study period, contrary to expectations based on international results. A recent Japanese study

reported improved functional outcomes with increase in use of acute reperfusion therapy in AIS patients over two decades.¹⁸ However, in our study, the IVT administration rate decreased post-2014, unlike in other countries where it has steadily risen in recent years.^{18,33,34} Notably, functional outcomes seemed to improve in IVT-treated patients during our study period (eTable 3). This suggests that the declining IVT rate might be a contributing factor to the lack of improvement in overall functional outcomes, despite an increase in EVT rates. This finding highlights a potential area for further investigation and improvement in stroke care strategies.

The decline in IVT rates in our study can be attributed to several factors: a higher proportion of patients with mild strokes, increased pre-stroke use of oral anticoagulants, and more comorbidities related to an aging population. The simultaneous decrease in IVT and increase in EVT, even among patients arriving within 4.5 hours of stroke or TIA onset, suggests that a rise in IVT-ineligible patients may be driving the reduced IVT rate. This is supported by findings from the Swiss Stroke Registry, which reported a notably low IVT rate in ischemic stroke patients with atrial fibrillation on NOACs.³² This contrasts with recent research suggesting the safety of IVT in patients who have taken NOACs within 48 hours before stroke onset.³⁵

The lack of improvement in OTA time highlights another potential area in need of improvement. Innovations in prehospital stroke systems of care are necessary, despite shortened DTN times and decreased ND after recanalization therapy (eTable 4, 5). Additionally, despite pivotal trials extending the recanalization therapy window,^{36,37} the use of perfusion imaging in patients arriving within 24 hours from the LNT and those with unclear onset (accounting for 41% of our study population) was lower than anticipated. This underutilization represents another potential area in need of novel strategies to improve stroke functional outcomes.

Our study's strengths include a large sample size and consistent data collection using standardized protocols since 2008, encompassing a wide range of outcome variables up to one year post-stroke. This allowed for a comprehensive examination of trends in stroke outcomes and their key determinants, such as stroke severity, etiological subtypes, and acute treatments.

However, there are study limitations to consider. First, our participants may not fully represent the South Korean stroke population at large, as the CRCS-K-NIH registry primarily includes tertiary or training hospitals engaged in continuous quality improvement activities. Thus, the rapid adoption of advanced stroke treatments and associated outcomes may be more favorable in our study than in general hospitals. Nonetheless, the demographics and clinical features of our study participants align with those in a national stroke audit program covering over 200 acute-care hospitals in South Korea (eTable 6). Additionally, as our study population was predominantly Korean and all participating hospitals were in South Korea, ethnic and cultural differences might limit the generalizability of our findings to other settings. Second, the observational nature of this study precludes determining causality between treatment changes and outcomes. For example, a detailed analysis to explain the lack of improvement in functional outcomes is beyond the study's scope, but warrants additional research to assess the impact of advanced treatments on functional recovery in real-world settings. Third, despite adjusting for age, sex, and stroke severity, residual confounding factors such as comorbidities, socioeconomic status, and medication adherence might have influenced the results.

In summary, our study reveals that in South Korea over the past decade, most clinical outcomes for patients with AIS or TIA have improved, with the notable exception of functional outcomes. During this period there also has been a steady increase in the use of treatments proven to be effective in acute stroke treatment and subsequent prevention.

However, our results highlight several challenges that need to be addressed to improve quality of stroke care. Additional efforts to develop prehospital stroke systems to reduce OTA time and increase the IVT rate promise to prove useful. Furthermore, research to investigate whether the observed trends, including decreased IVT rates and stagnation of functional outcomes, are unique to South Korea or represent broader trends in countries with older populations and represent an area worthy of risk mitigation related to the root causes of the findings.

Source of Funding: This research was supported by a fund (2023-ER1006-00) by Research of Korea Centers for Disease Control and Prevention.

Disclosure

The authors report no disclosures relevant to the manuscript.

References

1. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet* 2016;387:1723-1731.
2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981-992.
3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139-1151.
4. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;365:883-891.
5. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. *N Engl J Med* 2013;369:11-19.
6. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. *N Engl J Med* 2018;379:215-225.
7. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;355:549-559.
8. Amarenco P, Kim JS, Labreuche J, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. *N Engl J Med* 2020;382:9-19.
9. Lee SR, Choi EK, Han KD, Cha MJ, Oh S, Lip GYH. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study. *PLoS One* 2017;12:e0189495.
10. Rai AT, Crivera C, Kalsekar I, et al. Endovascular Stroke Therapy Trends From 2011 to 2017 Show Significant Improvement in Clinical and Economic Outcomes. *Stroke* 2019;50:1902-1906.
11. Abdul-Rahim AH, Fulton RL, Frank B, et al. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. *Eur J Neurol* 2015;22:1048-1055.
12. Park TH, Lee JK, Park MS, et al. Neurologic deterioration in patients with acute ischemic stroke or transient ischemic attack. *Neurology* 2020;95: e2178-e2191.
13. Lecoffre C, de Peretti C, Gabet A, et al. National Trends in Patients Hospitalized for Stroke and Stroke Mortality in France, 2008 to 2014. *Stroke* 2017;48:2939-2945.
14. Yafasova A, Fosbøl EL, Christiansen MN, et al. Time trends in incidence, comorbidity, and mortality of

ischemic stroke in Denmark (1996-2016). *Neurology* 2020;95:e2343-e2353.

15. Rucker V, Wiedmann S, O'Flaherty M, Busch MA, Heuschmann PU. Decline in Regional Trends in Mortality of Stroke Subtypes in Germany From 1998 to 2015. *Stroke* 2018;49:2577-2583.

16. Hsieh CY, Wu DP, Sung SF. Trends in vascular risk factors, stroke performance measures, and outcomes in patients with first-ever ischemic stroke in Taiwan between 2000 and 2012. *J Neurol Sci* 2017;378: 80-84.

17. Rucker V, Heuschmann PU, O'Flaherty M, et al. Twenty-Year Time Trends in Long-Term Case-Fatality and Recurrence Rates After Ischemic Stroke Stratified by Etiology. *Stroke* 2020;51:2778-2785.

18. Toyoda K, Yoshimura S, Nakai M, et al. Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes. *JAMA Neurol* 2022;79:61-69.

19. Bae HJ, Investigators C-K. David G. Sherman Lecture Award: 15-Year Experience of the Nationwide Multicenter Stroke Registry in Korea. *Stroke* 2022;53:2976-2987.

20. Kim BJ, Han MK, Park TH, et al. Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry. *Int J Stroke* 2014;9:514-518.

21. Roquer J, Rodriguez-Campello A, Gomis M, et al. Acute stroke unit care and early neurological deterioration in ischemic stroke. *J Neurol* 2008;255:1012-1017.

22. Seiffge DJ, Traenka C, Polymeris A, et al. Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. *Neurology* 2016;87:1856-1862.

23. Lackland DT, Roccella EJ, Deutsch AF, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. *Stroke* 2014;45:315-353.

24. Minnerup J, Wersching H, Unrath M, Berger K. Explaining the Decrease of In-Hospital Mortality from Ischemic Stroke. *PLoS One* 2015;10:e0131473.

25. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med* 2015;372:11-20.

26. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med* 2015;372:1009-1018.

27. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med* 2015;372:1019-1030.

28. Tan BYQ, Tan JTC, Cheah D, et al. Long-Term Trends in Ischemic Stroke Incidence and Risk Factors: Perspectives from an Asian Stroke Registry. *J Stroke* 2020;22:396-399.

29. Kim HC, Lee H, Lee HH, et al. Korea hypertension fact sheet 2021: analysis of nationwide population-based

data with special focus on hypertension in women. *Clin Hypertens* 2022;28:1.

30. Ornello R, Degan D, Tiseo C, et al. Distribution and Temporal Trends From 1993 to 2015 of Ischemic Stroke Subtypes: A Systematic Review and Meta-Analysis. *Stroke* 2018;49:814-819.

31. Choi JC, Lee JS, Park TH, et al. Effect of pre-stroke statin use on stroke severity and early functional recovery: a retrospective cohort study. *BMC Neurol* 2015;15:120.

32. Meinel TR, Branca M, De Marchis GM, et al. Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation. *Ann Neurol* 2021;89:42-53.

33. Marko M, Posekany A, Szabo S, et al. Trends of r-tPA (Recombinant Tissue-Type Plasminogen Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke. *Stroke* 2020;51:1240-1247.

34. Suolang D, Chen BJ, Wang NY, Gottesman RF, Faigle R. Temporal Trends in Stroke Thrombolysis in the US by Race and Ethnicity, 2009-2018. *JAMA* 2021;326:1741-1743.

35. Meinel TR, Wilson D, Gensicke H, et al. Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants. *JAMA Neurol* 2023;80:233-243.

36. Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. *Lancet* 2019;394:139-147.

37. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. *N Engl J Med* 2018;378:708-718.

Table 1. Secular Trends in Baseline Characteristics

Year of admission	Total	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	<i>P_{trend}</i>	<i>Adjusted P_{trend}*</i>	<i>β</i>
Number of patients	77,662	5,660	5,978	6,900	7,458	7,670	8,515	8,864	8,674	9,513	8,430			
Male, %	58.4	58.0	57.4	58.3	58.1	57.3	58.2	59.7	57.6	59.3	59.8	0.04	<.01	+
Age, y, mean (SD)														
Men	65.6 (12.7)	64.7 (12.7)	65.2 (12.6)	64.5 (12.8)	65.1 (13.0)	65.3 (12.4)	65.3 (12.6)	65.8 (12.7)	65.8 (12.8)	66.4 (12.8)	66.9 (12.4)	<.01	<.01	+
Women	71.6 (12.8)	70.5 (12.4)	70.7 (12.6)	70.7 (12.8)	71.0 (12.6)	71.2 (12.5)	71.4 (12.9)	71.9 (12.9)	72.5 (12.8)	72.4 (13.3)	72.9 (13.2)	<.01	<.01	+
Risk factors, %														
Hypertension	65.9	69.3	67.6	66.1	67.0	62.8	64.3	64.0	66.4	65.5	67.5	<.01	<.01	-
Newly diagnosed	9.0	11.2	9.4	9.7	7.7	7.3	8.7	8.7	9.4	9	9.7	0.12	0.12	+
Diabetes	32.4	33.4	32.6	32.2	32.5	31.2	31.6	31.5	31.9	32.8	34.6	0.18	0.87	+
Newly diagnosed	12.6	13.8	12.1	14.4	10.9	10.3	12.1	13.3	12.3	12.4	14.1	0.28	0.54	+
Dyslipidemia	30.7	39.1	32.0	27.9	26.0	25.6	30.8	30.5	28.6	32.8	34.6	0.13	<.01	+
Newly diagnosed	35.2	56.5	42.8	36.1	33	35.1	36.6	32.5	28.3	30.1	27.7	<.01	<.01	-
Atrial fibrillation	20.0	19.7	20.8	18.9	21.1	21.5	19.5	18.9	20.1	19.6	20.1	0.25	<.01	-
Newly diagnosed	45.9	46.4	38.5	40.9	46.5	46.7	45.6	47.7	45.9	48.4	49.6	<.01	<.01	+
History of stroke	20.7	21.3	20.4	20.8	21.1	20.1	20.2	19.9	20.7	21.2	21.7	0.31	0.15	+
Current smoking	23.0	25.0	25.4	25.7	24.0	20.5	22.9	23	21.2	21.9	22.4	<.01	<.01	-
Admitted via ER, %	89.1	87.7	86.8	87.1	87.6	87.6	88.5	90	90.6	92.2	90.6	<.01	<.01	+
Unclear onset, %	40.9	39.1	48.7	48.2	40.4	42.3	37.3	38.8	40.8	41.4	35.6	<.01	<.01	-
From FAT to arrival, h, median (IQR)	7.8 (2.2–34.2)	8.0 (2.3–33.2)	7.7 (2.1–34.4)	7.1 (2.0–30.6)	7.6 (2.0–34.6)	6.8 (1.8–31.1)	6.8 (1.9–29.5)	6.8 (1.7–29.9)	7.2 (1.8–31.9)	7.8 (1.9–32.7)	7.3 (1.9–32.0)	0.27	0.052	-
NIHSS at presentation														
Mean (SD)	5.3 (6.1)	5.4 (6.0)	5.5 (6.2)	5.5 (6.2)	5.7 (6.5)	5.4 (6.3)	5.3 (6.1)	5.2 (5.9)	5.3 (6.1)	5.0 (5.9)	5.1 (5.8)	<.01	<.01	-
NIHSS<4, %	49.7	47.8	47.9	48.7	47.6	49.6	49.6	49.3	49.6	53.0	52.1	<.01	<.01	+

NIHSS \geq 15, %	11.9	12.4	12.3	12.7	13.7	12.8	12.2	11.1	11.8	10.8	10.4	<.01	<.01	-
Pre-stroke, %														
Antiplatelets	28.7	30.7	29.4	29.1	30.2	30.2	26.6	26.9	28.2	28.1	29.0	<.01	<.01	-
Oral Anticoagulants in atrial fibrillation	41.1	28.4	25.2	29.0	36.1	38.3	45.3	43.6	48.3	51.4	56.1	<.01	<.01	+
Statin	20.8	15.1	17.7	17.4	19.1	20.3	20.0	21.0	22.7	25.0	25.2	<.01	<.01	+
TOAST subtypes, %**														
LAA	35.0	37.5	38.7	36.6	33.9	33	35.4	34	34.2	33.2	35.6	<.01	<.01	-
SVO	17.7	17.1	15.7	17.1	16.7	17.7	17.7	19.6	19.1	18	17.5	<.01	0.01	+
CE	21.2	22.0	22.2	21.4	23.1	23.3	21.0	20.1	21.2	20.1	19.2	<.01	<.01	-
OE	3.5	2.1	2.4	2.6	3.0	3.2	3.4	3.8	4.5	4.3	4.5	<.01	<.01	+
UE (2 or more)	4.4	4.8	4.4	4.3	4.2	4.8	4.6	4.7	3.8	4.2	4.4	0.29	0.01	-
UE (negative)	9.0	7.5	6.5	7.7	7.9	8.7	9.4	9.9	9.0	10.6	11.2	<.01	<.01	+
UE (incomplete)	9.1	9.0	10.0	10.4	11.1	9.3	8.6	8.0	8.2	9.6	7.5	<.01	<.01	-

ER, emergency room; FAT, first abnormal time; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism; OE, other etiology; UE, undetermined etiology.

The denominator of the newly diagnosed risk factor ratio is the frequency of risk factors.

* Adjusted for age and sex with random effects for the center.

** Among 70,450 patients excluding TIA

The β coefficient is indicated as + or - to indicate the direction of the slope and, if the directions of the univariate analysis and the multivariate analysis are different, they are separated with “/”.

Table 2. Secular Trends in Managements

Year of admission	Total	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	P_{trend}	Adjusted P_{trend}	β
Recanalization, %*														
IVT total	12.8	12.9	13.5	13.5	15.5	13.5	13.1	12.3	11.6	11.9	10.9	<.01	0.12	-
EVT total	8.4	5.4	6.0	6.1	8.1	8.4	8.3	8.6	10.4	9.9	10.6	<.01	<.01	+
IVT or EVT	17.1	14.7	16.1	16.0	18.8	17.5	17.5	16.8	17.8	17.5	17.5	<.01	<.01	+
DTN time ≤ 60 min, %**	86.4	82.1	85.4	91.0	88.8	87.0	86.8	83.7	84.8	87.2	86.5	0.88	0.73	-
DTN time ≤ 45 min, %**	65.4	55.2	62.3	71.8	71.7	70.6	65.1	60.9	62.9	63.4	67.3	0.85	0.81	-
DTP time ≤ 60 min, %***	10.3	7.3	10.4	8.3	7.2	11.8	9.2	11.2	10.5	9.8	13.4	<.01	0.62	+
Stroke unit care, %	61.4	60.8	55.2	51.8	54.6	52.8	57.1	65	72.2	71.1	67.5	<.01	<.01	+
Diagnostic evaluations, %														
PWI in patients ≤ 24 h from LNT	40.5	46.0	37.6	45.0	44.5	45.5	37.9	36.9	39.5	38.3	37.3	<.01	<.01	-
DWI	91.0	95.4	92.5	92.8	91.3	89.8	88.7	89.0	88.6	90.4	93.7	0.02	0.11	-
CTA/MRA	91.5	94.9	91.6	92.1	94.9	93.3	88.4	87.6	89.5	89.9	94.8	0.01	<.01	-
TTE	71.0	68.1	63.7	65.6	73.7	71.6	71.7	74.3	72.0	71.0	74.3	<.01	<.01	+
TEE	10.6	14.2	12.7	14.4	14.3	13.6	11.9	9.4	8.3	6.6	4.7	<.01	<.01	-
Holter monitoring	40.3	32.8	29.0	32.8	37.1	38.1	38.0	38.0	43.3	50.6	54.1	<.01	<.01	+
Discharge medication, %														
Single antiplatelets	34.0	44.8	43.4	45.3	39.5	38.1	33.2	30.8	27.5	25.9	21.8	<.01	0.11	-
Aspirin + Clopidogrel	37.6	28.8	25.9	26.9	30.8	32.2	36.3	40.5	44.3	47.4	51.7	<.01	<.01	+
Aspirin + Clopidogrel in mild stroke or TIA [†]	49.2	33.6	29.5	29.2	39.4	41.3	47.1	54.6	58.6	62.8	71.0	<.01	<.01	+
Warfarin	8.7	16.6	17.2	16.2	17.3	11.8	4.8	3.7	3.3	2.8	2.6	<.01	<.01	-
NOAC	9.6	0.0	0.0	1.1	1.0	7.2	12.6	13.9	15.8	16.9	17.2	<.01	<.01	+
Warfarin or NOAC for atrial fibrillation	71.4	63.6	56.4	66.3	66.8	68.1	72.2	73.7	78.0	79.6	79.7	<.01	<.01	+

Statin	86.3	75.8	81.6	85.7	85.4	83.8	85.5	87.8	89.1	91.4	91.1	<.01	<.01	+
Statin in LAA subtype	91.2	81.5	88.1	91.5	91.7	87.2	91.0	93.1	93.9	95.2	94.7	<.01	<.01	+

IVT, intravenous thrombolysis; EVT, endovascular thrombolysis; DTN, door-to-needle; DTP, door-to-puncture; PWI, perfusion-weighted image; LNT, last normal time; DWI, diffusion-weighted image; CTA, computed tomography angiography; MRA, MR angiography; TTE, transthoracic echocardiography; TEE, transesophageal echocardiography; TIA, transient ischemic attack; NOAC, new oral anticoagulants including apixaban, dabigatran, rivaroxaban, and edoxaban; LAA, large artery atherosclerosis.

* Among 70,450 patients, excluding those with TIA.

** Among 8,189 patients receiving IVT after excluding cases without data (n = 37) or with DTN >12 h (n = 35) or those with minus values due to IVT that has been performed at a referral hospital (n = 1,047).

*** Among 5,783 patients receiving EVT after excluding cases without data (n = 16) or with DTP >24 h (n = 72) or with minus values due to EVT that has been performed at a referral hospital (n = 66).

† Among patients with non-cardioembolic minor stroke (NIHSS ≤3) or high-risk TIA (relevant DWI lesion +) (n = 16,764).

The β coefficient is indicated as + or - to indicate the direction of the slope and, if the directions of the univariate analysis and the multivariate analysis are different, they are separated with “/”.

Table 3. Secular Trends in Stroke Outcomes

Year of admission	Total	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	<i>P</i> _{trend}	<i>Adjusted P</i> _{trend} *	<i>β</i>
ND in hospital, %	10.4	11.5	12.1	11.1	11.4	10.6	10.3	9.1	9.9	8.9	10.8	<.01	<.01	-
sHT in patients receiving recanalization therapy, %	3.0	5.3	2.8	3.2	2.9	2.5	2.6	2.5	3.0	3.6	2.7	0.16	0.50	-
Mean LOS, day (SD)	8.6 (4.6)	9.3 (4.9)	9.1 (4.9)	9.0 (4.9)	8.9 (4.7)	8.6 (4.5)	8.4 (4.5)	8.5 (4.6)	8.5 (4.6)	8.4 (4.5)	8.2 (4.5)	<.01	<.01	-
Outcome at 90 days, %														
mRS 0-1	50.2	52.0	49.9	46.9	48.7	49.6	50.3	49.6	50.9	51.9	51.5	<.01	0.06	+/-
mRS 0-2	65.2	65.4	64.0	64.2	64.6	66.0	65.9	65.7	64.6	65.8	65.3	0.38	<.01	+/-
Mortality	6.4	6.6	8	7.7	8.2	6.5	5.8	5.4	5.9	5.4	5.9	<.01	<.01	-
Outcome at 1 year, %														
mRS 0-1	53.4	55.2	53.7	50.6	50.7	52.3	53.7	53.4	55.1	55.5	53.4	0.02	0.47	+/-
mRS 0-2	66.1	66.6	65.3	65.1	64.5	65.9	67.1	66.0	66.3	67.1	65.2	0.43	0.19	+/-
Mortality	10.7	11.5	12.3	11.9	12.4	10.4	8.9	10	10.2	9.7	10.9	<.01	<.01	-
CI of recurrent stroke														
7 days	1.1	1.5	1.3	1.0	1.1	1.1	0.9	0.9	0.9	1.1	1.1	0.01	0.01	-
30 days	2.0	2.8	2.4	1.9	1.9	2.0	1.7	1.6	1.9	2.1	1.7	<.01	<.01	-
90 days	2.9	4.1	3.7	2.6	2.9	3.0	2.6	2.5	2.9	3.2	2.4	<.01	<.01	-
1 year	4.5	5.6	5.2	4.1	4.4	4.5	3.9	3.8	4.4	4.9	4.9	<.01	0.01	-

ND, neurologic deterioration; sHT, symptomatic hemorrhagic transformation; LOS, length of hospital stay; mRS, modified Rankin Scale; CI, cumulative incidence.

* Adjusted for age, sex, and initial National Institutes of Health Stroke Scale score with a random effect accounting for center.

The β coefficient is indicated as + or - to indicate the direction of the slope and, if the directions of the univariate analysis and the multivariate analysis are different, they are separated with “/”.




Figure. Changes of Recanalization Therapy Rates according to Hospital Arrival Time (A) and Various Clinical Features (B)

Figure Legends

During the study period, the IVT rate decreased in patients with various clinical conditions, while the EVT rate increased.

CE indicates cardioembolism; EVT, endovascular thrombectomy; IVT, intravenous thrombolysis; LNT, last normal time; OAC, oral anticoagulants.